Search research articles
Contact Us
Filters
Showing results (211-220 of 245) with videos related to
Page
of 25
Sort By:
Journal for Immunotherapy of Cancer
|
September 12, 2022
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Jordan W Conway, Robert V Rawson, Serigne Lo, et al.
Journal of the National Cancer Institute
|
June 15, 2026
Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma
Sophie E Orme, Serigne N Lo, Robyn P Saw, et al.
Annals of Surgical Oncology
|
May 18, 2024
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
Lisanne P Zijlker, Henry Chen, Andrew J Spillane, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2025
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Andrea Boutros, Amelia M Taylor, Isabel Li, et al.
The Lancet. Oncology
|
June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V Long, Robyn P M Saw, Serigne Lo, et al.
Journal of Translational Medicine
|
September 5, 2022
Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting
Mathias Seviiri, Richard A Scolyer, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2021
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies
Sydney Ch'ng, Semra Uyulmaz, Matteo S Carlino, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 16, 2025
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Jorja Braden, Alison Potter, Robert V Rawson, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
Human Molecular Genetics
|
July 28, 2020
Multiplex melanoma families are enriched for polygenic risk
Matthew H Law, Lauren G Aoude, David L Duffy, et al.
Page
of 25
Search research articles
Search
Showing results (211-220 of 245) with videos related to
Sort By:
Page
of 25
Journal for Immunotherapy of Cancer
|
September 12, 2022
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Jordan W Conway, Robert V Rawson, Serigne Lo, et al.
Journal of the National Cancer Institute
|
June 15, 2026
Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma
Sophie E Orme, Serigne N Lo, Robyn P Saw, et al.
Annals of Surgical Oncology
|
May 18, 2024
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
Lisanne P Zijlker, Henry Chen, Andrew J Spillane, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2025
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Andrea Boutros, Amelia M Taylor, Isabel Li, et al.
The Lancet. Oncology
|
June 8, 2019
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF<sup>V600</sup> mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Georgina V Long, Robyn P M Saw, Serigne Lo, et al.
Journal of Translational Medicine
|
September 5, 2022
Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting
Mathias Seviiri, Richard A Scolyer, D Timothy Bishop, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2021
Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies
Sydney Ch'ng, Semra Uyulmaz, Matteo S Carlino, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 16, 2025
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Jorja Braden, Alison Potter, Robert V Rawson, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
Human Molecular Genetics
|
July 28, 2020
Multiplex melanoma families are enriched for polygenic risk
Matthew H Law, Lauren G Aoude, David L Duffy, et al.
Page
of 25